Neuromyelitis optica

disorder

SNOMED 25044007CUI C0027873

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Treatments & Interventions

Inebilizumab

substance

Satralizumab

substance

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

Autoimmune antibody positivity

Very frequent (80-99%)HP:0030057

Eye pain

Very frequent (80-99%)HP:0200026

Inflammation of spinal cord

Very frequent (80-99%)HP:0012486

Leg paralysis

Very frequent (80-99%)HP:0010550

Neuronal loss in CNS

Very frequent (80-99%)HP:0002529

Optic neuritis

Very frequent (80-99%)HP:0100653

Peripheral demyelination

Very frequent (80-99%)HP:0011096

Poor bladder function

Very frequent (80-99%)HP:0000009

Sensory impairment

Very frequent (80-99%)HP:0003474

Visual loss

Very frequent (80-99%)HP:0000572

Abnormal brain morphology

Frequent (30-79%)HP:0012443

Anti-aquaporin 4 antibody positivity

Frequent (30-79%)HP:0033342

Anti-MOG antibody positivity

Occasional (5-29%)HP:0032492

Cerebrospinal fluid pleocytosis

Occasional (5-29%)HP:0012229

Hiccups

Occasional (5-29%)HP:0100247

Nausea

Occasional (5-29%)HP:0002018

Respiratory failure

Occasional (5-29%)HP:0002878

Related Conditions

Optic neuritis(parent)

Immune-mediated neuropathy(parent)

Spinal demyelination(parent)

Myelitis(parent)

Quick Facts

SNOMED CT: 25044007
UMLS CUI: C0027873
Fully Specified Name: Neuromyelitis optica (disorder)
Specialists: 0
Diagnostic Biomarkers: 0
HPO Phenotypes: 17
Known Treatments: 2

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.